These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38072070)

  • 41. Selection of optimal therapy for chronic stable angina.
    Thadani U
    Curr Treat Options Cardiovasc Med; 2006 Feb; 8(1):23-35. PubMed ID: 16401381
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.
    Banon D; Filion KB; Budlovsky T; Franck C; Eisenberg MJ
    Am J Cardiol; 2014 Mar; 113(6):1075-82. PubMed ID: 24462341
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
    Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
    Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Re-thinking angina.
    Conti CR
    Clin Cardiol; 2007 Feb; 30(2 Suppl 1):I1-3. PubMed ID: 18373324
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C; Newby LK
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
    Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Katz A; Jones PG; Olmsted A; Belardinelli L; Chaitman BR
    J Am Coll Cardiol; 2013 May; 61(20):2038-45. PubMed ID: 23500237
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ivabradine: the evidence of its therapeutic impact in angina.
    Marquis-Gravel G; Tardif JC
    Core Evid; 2008 Jun; 3(1):1-12. PubMed ID: 20694080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spotlight on ranolazine in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Am J Cardiovasc Drugs; 2006; 6(5):357-9. PubMed ID: 17083271
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ranolazine, a new antianginal drug.
    Tavazzi L
    Future Cardiol; 2005 Jul; 1(4):447-55. PubMed ID: 19804144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [New pharmacological approaches to ischemic heart disease].
    Raddino R; Della Pina P; Gorga E; Brambilla G; Regazzoni V; Gavazzoni M; Dei Cas L
    G Ital Cardiol (Rome); 2012 Oct; 13(10 Suppl 2):50S-54S. PubMed ID: 23096376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficiency of ranolazine in the patient with microvascular angina, atrial fibrillation and migraine.
    Osovska NY; Kuzminova NV
    Wiad Lek; 2016; 69(6):832-837. PubMed ID: 28214825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short-term effects of ivabradine in patients with chronic stable ischemic heart disease.
    Zaky H; Elzein H; Alsheikh-Ali AA; Al-Mulla A
    Heart Views; 2013 Apr; 14(2):53-5. PubMed ID: 23983908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [New agents for the therapy of angina pectoris].
    Meinertz T; Köster R
    Internist (Berl); 2011 Jul; 52(7):894-6, 898-900. PubMed ID: 21713611
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.
    Scirica BM; Belardinelli L; Chaitman BR; Waks JW; Volo S; Karwatowska-Prokopczuk E; Murphy SA; Cheng ML; Braunwald E; Morrow DA
    Europace; 2015 Jan; 17(1):32-7. PubMed ID: 25210025
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
    Sossalla S; Maier LS
    Pharmacol Ther; 2012 Mar; 133(3):311-23. PubMed ID: 22133843
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
    Ruzyllo W; Tendera M; Ford I; Fox KM
    Drugs; 2007; 67(3):393-405. PubMed ID: 17335297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ranolazine (Ranexa) for chronic stable angina.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Jun; (99):1-6. PubMed ID: 17595750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Ivabradine in Combination with Beta-Blockers in Patients with Stable Angina Pectoris: A Systematic Review and Meta-analysis.
    Nedoshivin A; Petrova PTS; Karpov Y
    Adv Ther; 2022 Sep; 39(9):4189-4204. PubMed ID: 35842897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis.
    Manolis A; Kallistratos M; Poulimenos L; Zamfir T; Thomopoulos C
    Hellenic J Cardiol; 2023; 71():26-32. PubMed ID: 36481415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ranolazine: a review of its use in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Drugs; 2006; 66(5):693-710. PubMed ID: 16620147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.